Filing Details
- Accession Number:
- 0000899243-18-002765
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-02-02 20:17:09
- Reporting Period:
- 2018-01-31
- Accepted Time:
- 2018-02-02 20:17:09
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1629137 | Global Blood Therapeutics Inc. | GBT | Pharmaceutical Preparations (2834) | 274825712 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1650131 | Peter Radovich | C/O Global Blood Therapeutics, Inc. 171 Oyster Point Blvd., Suite 300 South San Francisco CA 94080 | See Remarks | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2018-01-31 | 1,600 | $0.00 | 6,221 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2018-01-31 | 554 | $57.90 | 5,667 | No | 4 | F | Direct | |
| Common Stock | Acquisiton | 2018-02-01 | 3,000 | $0.00 | 8,667 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2018-02-01 | 1,038 | $59.60 | 7,629 | No | 4 | F | Direct | |
| Common Stock | Disposition | 2018-02-01 | 812 | $57.30 | 6,817 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | F | Direct | |
| No | 4 | M | Direct | |
| No | 4 | F | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Restricted Stock Units | Disposition | 2018-01-31 | 1,600 | $0.00 | 1,600 | $0.00 |
| Common Stock | Restricted Stock Units | Disposition | 2018-02-01 | 3,000 | $0.00 | 3,000 | $0.00 |
| Common Stock | Stock Option (Right to Buy) | Acquisiton | 2018-02-01 | 26,500 | $0.00 | 26,500 | $59.60 |
| Common Stock | Restricted Stock Units | Acquisiton | 2018-02-01 | 17,000 | $0.00 | 17,000 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 7,200 | No | 4 | M | Direct | ||
| 18,000 | No | 4 | M | Direct | ||
| 26,500 | 2028-01-31 | No | 4 | A | Direct | |
| 17,000 | No | 4 | A | Direct |
Footnotes
- Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.
- Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 1,600 shares of Common Stock underlying the Reporting Person's RSUs.
- Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 3,000 shares of Common Stock underlying the Reporting Person's RSUs.
- This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- On August 11, 2017, the Reporting Person was granted 12,000 RSUs, which vest in installments upon the achievement of specified market capitalization milestones of the Issuer on or before December 31, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting milestone. On January 31, 2018, one of the performance milestones was achieved, resulting in the vesting of 1,600 shares of Common Stock underlying the RSU grant. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
- On January 17, 2017, the Reporting Person was granted 24,000 RSUs, which vest in equal semi-annual installments over 4 years from February 1, 2017, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
- The shares underlying the option vest in 16 equal quarterly installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
- The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
Billionaire Hedge Funds
